apple
- 25 Mar 2004 20:47
rvitler
- 18 Jan 2005 15:14
- 312 of 1451
Used to have that one yrs ago, but not quite in OXB league, I strogly believe that 05 will be OXB breakout yr and 50p +
pachandl
- 18 Jan 2005 15:23
- 313 of 1451
Some suggestion from sources unknown (London broker) that OXB might be a possible target. Nothing known - and could easily be a rumour started to drum up some trading in OXB.
Oakapples142
- 19 Jan 2005 08:03
- 315 of 1451
Panchandl - Great so what does your crystal ball say this morning. Any views on the long term - I have never done that well with mergers but this could be an exception.
pachandl
- 19 Jan 2005 08:28
- 316 of 1451
Depends on the drug pipeline of the other firm. I cannot find anything out about it so far.
Oakapples142
- 19 Jan 2005 08:36
- 317 of 1451
Interesting that two others in my portfolio are leaping this morning MDW and CEN and SKP holding its own (I cant see its any of them but you never know) I know that I have too many biotech stocks for my health - but this mornng the medicine tastes fine.
robstuff
- 19 Jan 2005 11:17
- 318 of 1451
A takeover is more likely at this price unless they merge with a small co. I really hope it's not the latter which would dilute this great co. I'd prefer it remains autonomous as one day this technolgy will be worth pounds per share and to sell out at these levels would be awful. Expect another big rise tomorrow, could hit 30p by end of week, maybe more.
ethel
- 19 Jan 2005 11:29
- 319 of 1451
What would a takeover price be for OXB?30p seems to be too low.Also,I can't see any really BIG money in on this news.Why not?
pachandl
- 19 Jan 2005 11:41
- 320 of 1451
The rns refers to a merger - not a take over. Thus, it is the range of pipeline drugs that the other co brings to the deal which is so important. I accept the possibility that the mereger might involve a much larger company (such as Biogen - mooted elsewhere) but this is very unlikely because a take-over would be the more sensible option. The reverse is also true if OXB are dealing with a much smaller company. I have no information about this possible merger but I wonder whether Vernalis, or perhaps Cenes, might be involved.
grevis2
- 19 Jan 2005 13:20
- 321 of 1451
Top % Gainers
# EPIC Name Price Chg %
1 DBE Dunham-bush Ord 2.5p 2.0 0.875 77.78
2 IGA Ingenta Ord 1p 4.225 0.875 26.12
3 EVS Envesta Ord 1p 2.9 0.55 23.4
4 NMT Nmt Group Ord 4 67.5 11.5 20.54
5 MCR Mercator Ord 1p 9.5 1.375 16.92
6 PMG Pc Medics Grp Ord 0.25p 0.7 0.1 16.67
7 EIC Eicom Ord 0.5p 0.55 0.075 15.79
8 AXO Axon Grp. Ord 1p 173.5 23.5 15.67
9 OXB Oxford Biomed. Ord 1p 22.25 3.0 15.58
robstuff
- 19 Jan 2005 14:01
- 322 of 1451
I can't see a merger going ahead under 30p equiv, that would severeley undervalue this company. A merger once announced I think would really increase the sp for the other co. concerned as it will have to be a similar sized co. and OXB is so undervalued, it will bring so much to the enlarged co. If a much larger co., then at these prices they may aswell bid for it outright but if that is not happening, the value of the the experts in OXB is obviously too much to lose and therefore a merger is the only option. OXB should not merge but remain independent and enter license agreements/affiliations instead.
rvitler
- 19 Jan 2005 14:30
- 323 of 1451
robstuff - not quite sure I understand your logic but agree that a takeover would be more likely but I also think it would be extremely beneficial to merge with another with similar expertise/complimentary products - a sharing of brains and economies of scale and more power in contracting deals. Also think we'll see 30p over the next week, as it's been recognised how undervalued this co is and the articles in the press should highlight that.
ethel
- 19 Jan 2005 14:31
- 324 of 1451
By market cap.Vernalis is a much smaller co.than OXB.However,it has Frovatripran to sell...bringing in some cash,as well .Don't you think that Biogen has some influence in this scenario,as it is the third largest bio-tech.co. i n the world,and would be interested in encouraging a merger between OXB and VER. with a base in Oxford which is internationally respected as a centre of medical research.As both Ver and Oxb are researching Parkinsons there would be immediate advantages to their closer co-operation in this field,which has great possibilities for alleviating the suffering of millions of people,worldwide.My question is,how high can we expect the price to rise and how long do we have to wait for the next rns?They were pretty sharpish,this am.
hangon
- 19 Jan 2005 15:13
- 325 of 1451
I'm not sure about this "merger" business - I thought OXB had sufficient cash (and good City connections if they need more) - - -and it looks like they have several products doing quite nicely, although none is ready for Market just yet.
That said, is OXB looking for a partner? - well yes they could be, but I suspect it would be someone already in the frame, OR someone that is already in their target market and who would have the right connections to exploit the technology. That might mean a US-Pharma that can see the potential and wants to move "now" before the value rises (as products get closer to Market).
Or it could be a UK pharma = that knows OXB, likes what they see and needs a slice of the action to bolster their own "miserable" pipeline.
((we hear that major pharmas haven't got anything new for some years)) - So maybe a "First-Late-mover"
So the very word "merger" looks like it is on OXB's Terms - it's not a buy-out as the larger co wants the team to remain in place (presumably), so we'll just have to wait for more news.... I bought some to help move the price, but it was too little and probably too late.....I read (here) that someone believes 30p is right - but frankly any price could be quoted. - As a long-term investor I'd like to see some profit "down the line" - call it a reward for patience - it's bad enough being shafted by firms that go "belly-up" like Mayflower, Marconi, NMT (in the news again Oh yes that will be nice, NMT were 28 not that long ago when you factor-in the CON-solidation, do I make a point? ) - - - but it would be more than disapointing if we were shafted by an OXB deal that enhances Management(of OXB) whilst discards shareholders that have stayed the course. I suppose that, of all my holdings this is really the last one that should still come good; yet......... I see a Fogging, then it was gone?
Regards.
hangon
- 19 Jan 2005 15:20
- 326 of 1451
Sorry, I should have entered a plea - if anyone is in contact with the Company
Can OXB make any deal palitable for PEP and ISA holders? So often we have a forced sale on our hands and the Market-makers then drop the price knowing XXX shares will be sold as they no-longer meet the Taxmans Rules (etc).....PEP and ISA holdings really are long-term committments, so it's only right that fully-listed Companies bear in mind their elevated status and the need to consider all Classes of Holders.
I'll step off the soapbox now.
ethel
- 19 Jan 2005 15:43
- 327 of 1451
Is 40p a reasonable target?
rvitler
- 19 Jan 2005 16:13
- 328 of 1451
some good points hangon and I agree, it will be on OXB terms and I still think there may be a fight for the co, maybe a takeover bid as so often is the case when it comes to competitor's attention. There may have been several cos eyeing up OXB waiting for the right time, now that their technology is close to being commercial the value could soar!
ethel
- 19 Jan 2005 16:27
- 329 of 1451
Biogen has collaborative agreements with Oxb and Ver;so,they are familiar with each other and it would enable Biogen to have a stronger presence in the U.K. if it was financially involved in the new company.Have put a stop in at 21p as I can't watch this tomorrow.Could be very volatile.
Hangon you have all my sympathies.So often,the shareholders are considered to be interfering nuisances.The small shareholder is risking HIS/HER OWN MONEY....unlike the pension fund managers.
Fred1new
- 19 Jan 2005 16:38
- 330 of 1451
Hangon, I feel we could compare "Dogs" and do agree management buyouts and some take overs and mergers are not very rewarding sometimes. I have looked at my investing techniques for the last 10years wondering if I would make the same mistakes again. I hope not. But at the time of buying those "dogs", I knew the risks involve, inherent in all small company shares, which were bought for their higher returns. Some of those buys have been good, (RTD, PDX,CASH, TFC as egs) which more than made up for the losses. It would be nice if the government allowed the same breadth of securities to be bought in a PEP or ISA as a SIPP. The rules were brought in as a protection for the punter, but could be changed with warnings to the punters.)
But reviewing my strategies changing the type of company I buy will buy in future will reduce the number of buys of non-profit making companies, with good ideas and high R&D not paid for out of earnings. This applies to the likes of OXB.
I think any price above 35p but anything above 30 p will be a bonus